US-based biotech Precision Biosciences raises $25.6m in series A backing in a round backed by Osage and others.
University investment consortium Osage University Partners is one of several backers investing in US-based biotech Precision Biosciences.
The $25.6m series A round was led by Venbio, and joined by Osage, Baxter Ventures, Fidelity Biosciences, Amgen Ventures, the Longevity Fund, and others. Robert Adelman of Venbio and Ben Auspitz of Fidelity will join the company’s board as part of the deal.
Precision is developing genome editing technology called Arcus, which is backed by a number of patents. Precision does not implicitly…